One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Search from 250 M+ research papersSearch from 250 M+ research papers
Open Accesshttps://doi.org/10.1182/blood-2018-99-115129
Copy DOI Journal: Blood |  Publication Date: Nov 29, 2018 |
 Citations: 7 |
Affiliation: Hôpital Saint-Louis, Délégation Paris 7, Université Paris Cité, Hospital Ramos Mejía, The University of Texas Health Science Center, The University of Texas Health Science Center at San Antonio, The University of Texas MD Anderson Cancer Center, Changsha Mining and Metallurgy Research Institute (China), University of Florence, Johannes Wesling Klinikum Minden, Saint Agnes Hospital, Novartis (France), University of Naples Federico II, Semmelweis University, Charité - Universitätsmedizin Berlin, Novartis (Switzerland), Istituti di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo Fondazione, University of Yamanashi, Guy's and St Thomas' NHS Foundation Trust, Hospital del Mar Research Institute, Autonomous University of Barcelona, Osaka City University, Royal Brisbane and Women's Hospital, Ziekenhuisnetwerk Antwerpen Stuivenberg, Ospedale di Circolo e Fondazione MacchiLong-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
